Dmytruk Mark E. 的 Form 4/A 修正申報
修正Ginkgo Bioworks Holdings, Inc.（DNA），2022/11/7 申報
- 申報編號
- 0000899243-22-035333
- 申報時間
- 2022/11/7
- 交易日
- 2022/10/5-10/6
- 申報延遲
- 33 天
- 10b5-1 計畫
- 表單沒有這欄（2023 年以前）
- 原始申報日
- 2022/10/7
這份申報列了 2 筆非衍生性交易、1 筆衍生性交易。公開市場賣出合計 $90.8 萬。交易後 33 天申報。
這份修正申報取代了 0000899243-22-033322（2022/10/7 申報）。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Dmytruk Mark E.CIK 0001873507 | 高階主管（見申報備註） |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2022/10/5 | Class A Common Stock | M行使選擇權取得 | +618,242 | –F1 | – | 627,344 | 直接 | |
| 2022/10/6 | Class A Common Stock | S賣出處分 | −279,255 | $3.25 | −$907,578.75 | 348,089 | 直接 |
衍生性證券（表 II）
選擇權、認股權證、限制型股票單位等。股數是標的股票的股數；單價與金額是衍生證券本身的價格，交易後持有是衍生證券的單位數。
| 交易日 | 證券 | 交易 | 標的股數 | 單價 | 金額 | 交易後持有 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2022/10/5 | Restricted Stock Units | M行使選擇權處分 | −618,242 | –F1 | – | 1,899,021 | 直接 |
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
Represents the conversion of shares of Restricted Stock Units ("RSUs") to Class A Common Stock. On October 5, 2022, the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for 618,242 vested RSUs. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.
表 I 有 1 筆、表 II 有 1 筆交易的價格引用這則附註。
- F2
Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligation to be funded by a "sell to cover" transaction.
- F3
On March 14, 2022, the Reporting Person filed a Form 4 that reported RSUs on a consolidated basis with holdings of Class B Common Stock. Because the Issuer has the ability to settle such RSUs with shares of Class A Common Stock or cash upon vesting, RSUs will be reported separately from shares of Class B Common Stock in future reports. In addition to the RSUs reported herein, the Reporting Person beneficially owns 658,133 shares of Class B Common Stock, which includes shares of Class B Common Stock that are subject to vesting conditions.
備註
Chief Financial Officer This Form 4 amends and restates the Form 4 filed by the Reporting Person on October 7, 2022 to correct an error in Table II.